Cisplatin-induced vomiting depends on circadian timing

Chronobiology International

Volumn 18, Issue 5, 2001, Pages 851-863

  Kobayashi, Minoru ^a,b   To, Hideto ^b   Tokue, Akihiko ^b   Fujimura, Akio ^b   Kobayashi, Eiji ^b  

^a Dorn Medical Center   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronotherapy; Cisplatin and furosemide; Vomiting

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CREATININE; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; FUROSEMIDE; METOCLOPRAMIDE; N ACETYL BETA GLUCOSAMINIDASE; ONDANSETRON; PIRARUBICIN; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSSOVER PROCEDURE; HUMAN; HYDRATION; MALE; NAUSEA; NEPHROTOXICITY; PROPHYLAXIS; UREA NITROGEN BLOOD LEVEL; UROGENITAL TRACT CANCER; VOMITING;

ACETYLGLUCOSAMINIDASE; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CHRONOTHERAPY; CISPLATIN; CREATININE; CROSS-OVER STUDIES; DIURETICS; FUROSEMIDE; HUMANS; KIDNEY; MALE; MIDDLE AGED; ONDANSETRON; UROGENITAL NEOPLASMS; VOMITING;

EMESIS;

EID: 0035208609     PISSN: 07420528     EISSN: None     Source Type: Journal    
DOI: 10.1081/CBI-100107520     Document Type: Article

References (30)

1. Mechanism of cisplatin nephrotoxicity
2. Peripheral neurotoxicity associated with cis-dichlorodiammineplatinum (II) treatment
3. A review of clinical experience with cis-platin diammine chloride
4. Nausea and vomiting as major complications of cancer chemotherapy
5. Toxic effects of cis-dichlorodiammineplatinium(II) in man
6. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats
7. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing
8. Circadian timing of cancer chemotherapy
9. Sleep protects against chemotherapy induced emesis
10. Lack of anti-emetic effect of high-dose metoclopramide
11. Inhibition of cisplatin-induced vomiting by selective 5 hydroxytryptamine M-receptor antagonism
12. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis
13. Anti-emetic properties of the 5HT3 antagonist, GR38032F
14. Comparison of the 5-Hydroxytryptamine-3(Serotonin) antagonist ondansetron(GR38032) with high-dose metoclopramide in the control of cisplatin-induced emesis
15. Simple, rapid spectrophotometry of urinary N-Acetyl-(-D-gulucosaminidase, with use of a new chromogenic substrate
16. Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy
17. Circadian cancer therapy
18. High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity
19. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis
20. Effects of mannitol and furosemide diuresis on cis-diamminedichloroplatinum(II) antitumor activity and toxicity to host-renewing cell populations in rats
21. Effect of a forced diuresis on the distribution and excretion (via Urine and Bile) of 195m platinum when given as 195m platinum cis-diamminedichloroplatinum(II)
22. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats
23. Daily variation in the effects of furosemide in rats
24. Circadian time dependent tissue uptake of cisplatin and carboplatin following repeated administration: Relationship with drug toxicities
25. Rhythms in tumor markers
26. Circadian-system alterations during cancer processes: A review
27. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status
28. Diurnal cortisol rhythm as a predictor of breast cancer survival
29. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma
30. Alteration of physiological circadian time structure of six plasma proteins in patients with advanced cancer